Research

INSERM U1084 Experimental and clinical neuroscience laboratory

Themes developed in the Inserm U1084 unit: Experimental and clinical neuroscience laboratory  (LNEC) (Pr M. JABER).

Glial tumors: Study and characterization of glioma stem cells in terms of sensitivity to new and conventional therapies, intrinsic radio-sensitivity, signaling and genes implicated in their migration and relationship with the micro-environment.  Genetic study of low-grade gliomas in collaboration with the neurosurgery, neurology, medical oncology, radiotherapy and pathological anatomy departments.

Progression and dissemination of tumour cells university team (PRODICET)

A mono-thematic university team dedicated to cancer research has been created lately (2020-2021) and will be evaluated by the HCERES.

The team members are part of several Poitiers research units (INSERM U1082 and U1084 units, EA 4331 unit) or newly recruited at Poitiers University. To create this structure, they merged their respective thematics (colorectal cancer, breast cancer, primary and secondary brain tumours, cancer stem cells, angiogenesis and tyrosine kinase receptors) towards a topical, competitive common project, that considers each of its members expertise.

Theme developped in the PRODICET team :

The study and understanding of primary and secondary brain tumours initiation and progression mecanisms, around two brain tumours related topics :

  • infiltrating and locally invasive gliomas, primary central nervous system tumours.
  • intracerebral metastasis caused by several types of tumours, including colorectal cancer and breast cancer.

Research projects are sponsored by the French national cancer institute, the Cancer league, “Sport et collection” association, and “En avant la vie” association.

Translational research beyond cerebral tumours

As regards all the other cancer pathologies studied in the laboratory (colorectal tumors, pulmonary and melanomic adenocarcinomas…), the observations on patients amassed during routine testing can be widened and deepened, which implies close cooperation between biologists and clinicians. Clarifications and comparisons of techniques in molecular genetics can also lead to research.

CML model: Study of the phenomenon of persistent leukemic stem cells; study of the phenomenon of genomic instability associated with the hematopoietic niche; analysis of the leukemic niche and study of the phenomenon of senescence (in relation to the persistence and resistance of leukemic stem cells to tyrosine kinase inhibitors).

These research projects are supported by: the Ligue contre le cancer, the Sport et collection association and the En avant la vie association.

Main publications of the last three years :  

  1. Tachon G, Cortes U, Richard S, Martin S, Milin S, Evrard C, Lamour C and Karayan-Tapon L. Targeted RNA-sequencing assays, a step forward compared to FISH and IHC techniques? Cancer Medecine. 2019. Oct 25.
  2. Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers (Basel). 2019 Oct 15;11(10).
  3. Tachon G, Masliantsev K, Rivet P, Petropoulos C, Godet J, Milin S, Wager M, Guichet PO, Karayan-Tapon L. Prognostic significance of MEOX2 in gliomas. Mod Pathol. 2019 Jun;32(6):774-786.
  4. Roussille P, Tachon G, Villalva C, Milin S, Frouin E, Godet J, Berger A, Emambux S, Petropoulos C, Wager M, Karayan-Tapon L*, Tougeron D*. Pathological and Molecular Characteristics of Colorectal Cancer with Brain Metastases. Cancers (Basel). 2018 Dec 10;10(12).  *equal contribution
  5. Tachon G, Cortes U, Guichet PO, Rivet P, Balbous A, Masliantsev K, Berger A, Boissonnade O, Wager M, Karayan-Tapon L. Cell Cycle Changes after Glioblastoma Stem Cell Irradiation: The Major Role of RAD51. Int J Mol Sci. 2018 Oct 3;19(10).
  6. Guichet PO, Masliantsev K, Tachon G, Petropoulos C, Godet J, Larrieu D, Milin S, Wager M, Karayan-Tapon L. Fatal correlation between YAP1 expression and glioma aggressiveness: clinical and molecular evidence. J Pathol. 2018 Oct;246(2):205-216.
  7. Petropoulos C, Guichet PO, Masliantsev K, Wager M, Karayan-Tapon L. Functional invadopodia formed in glioblastoma stem cells are important regulators of tumor angiogenesis. Oncotarget. 2018 Apr 17;9(29):20640-20657.
  8. Tachon G, Frouin E, Karayan-Tapon L, Auriault ML, Godet J, Moulin V, Wang Q, Tougeron D. Heterogeneity of mismatch repair defect in colorectal cancer and its implications in clinical practice. Eur J Cancer. 2018 May;95:112-116.
  9. Masliantsev K, Pinel B, Balbous A, Guichet PO, Tachon G, Milin S, Godet J, Duchesne M, Berger A, Petropoulos C, Wager M, Karayan-Tapon L. Impact of STAT3 phosphorylation in glioblastoma stem cells radiosensitization and patient outcome. Oncotarget. 2017 Dec 16;9(3):3968-3979.
  10. Rimbert J, Tachon G, Junca A, Villalva C, Karayan-Tapon L*, Tougeron D*. Association between clinicopathological characteristics and RAS mutation in colorectal cancer. Mod Pathol. 2018 Mar;31(3):517-526. *equal contribution
  11. Junca A, Villalva C, Tachon G, Rivet P, Cortes U, Guilloteau K, Balbous A, Godet J, Wager M, Karayan-Tapon L. Crizotinib targets in glioblastoma stem cells. Cancer Med. 2017 Nov;6(11)
  12. Pinel B, Duchesne M, Godet J, Milin S, Berger A, Wager M, Karayan-Tapon L. Mesenchymal subtype of glioblastomas with high DNA-PKcs expression is associated with better response to radiotherapy and temozolomide. J Neurooncol. 2017 Apr;132(2):287-294.
  13. Pagliaro S, Desterke C, Acloque H, Chomel JC, de Souza L, Hugues P, Griscelli F, Foudi A, Bennaceur-Griscelli A, Turhan AG. Single cell transcriptome in chronic myeloid leukemia (CML): pseudotime analysis reveals evidence of embryonic and transitional stem cell states. Exp Hematol. 2020 April in press.
  14. Cayssials E, Torregrosa-Diaz J, Gallego-Hernanz P, Tartarin F,  Systchenko T, Maillard N, Desmier D, Machet A, Fleck E, Corby A, Motard C, Denis G, Herbelin A, Gombert JM, Roy L, Ragot S, Leleu X, Guilhot F, Chomel JC. Low-dose tyrosine kinase inhibitors prior to treatment discontinuation do not impair treatment-free remission in chronic myeloid leukemia patients: results of a retrospective study. Cancer. 2020 April in press.
  15. Turhan AG, Hugues P, Sorel N, Desterke C, Bourhis JH, Bennaceur-Griscelli A, Chomel JC. Evidence of BCR-ABL1-positive progenitor spread in blood during molecular recurrence after TKI discontinuation in chronic myeloid leukemia (CML). Leuk Lymphoma. 2020 Mar 3:1-5.
  16. Gallego Hernanz MP, Sorel N, Bouyer S, Desmier D, Chollet M, Maillard N, Brizard F, Moya N, Diaz JMT, Leleu X, Chomel JC. Longitudinal clonal architecture of acute myeloid leukemia with NPM1 driver insertion, early TET2 mutations and secondary e6a2 BCR-ABL1 rearrangement. Leuk Lymphoma. 2020 Feb 20:1-5.
  17. Cayuela JM, Chomel JC, Coiteux V, Dulucq S, Escoffre-Barbe M, Etancelin P, Etienne G, Hayette S, Millot F, Nibourel O, Nicolini FE, Réa D. Recommendations from the French CML Study Group (Fi-LMC) for BCR-ABL1 kinase domain mutation analysis in chronic myeloid leukemia. Bull Cancer. 2020 Jan;107(1):113-128.
  18. Flamant S, Chomel JC, Desterke C, Féraud O, Gobbo E, Mitjavila-Garcia MT, Foudi A, Griscelli F, Turhan AG, Bennaceur-Griscelli A. Global MicroRNA Profiling Uncovers miR-206 as a Negative Regulator of Hematopoietic Commitment in Human Pluripotent Stem Cells. Int J Mol Sci. 2019 Apr 8;20(7).
  19. Cayssials E, Jacomet F, Piccirilli N, Lefèvre L, Roy L, Guilhot F, Chomel JC, Leleu X, Gombert JM, Herbelin A, Barbarin A. Sustained treatment-free remission in chronic myeloid leukaemia is associated with an increased frequency of innate CD8(+) T-cells. Br J Haematol. 2019 Jul;186(1):54-59.
  20. Gallego Hernanz MP, Torregrosa Diaz JM, Sorel N, Bobin A, Dindinaud E, Bouyer S, Desmier D, Brizard F, Leleu X, Maillard N, Chomel JC. Long-term molecular remission in a patient with acute myeloid leukemia harboring a new NUP98-LEDGF rearrangement. Cancer Med. 2019 Apr;8(4):1765-1770.
  21. Desterke C, Voldoire M, Bonnet ML, Sorel N, Pagliaro S, Rahban H, Bennaceur-Griscelli A, Cayssials E, Chomel JC, Turhan AG. Experimental and integrative analyses identify an ETS1 network downstream of BCR-ABL in chronic myeloid leukemia (CML). Exp Hematol. 2018 Aug;64:71-83.
  22. Girerd S, Tosca L, Herault O, Vignon C, Biard D, Aggoune D, Dkhissi F, Bonnet ML, Sorel N, Desterke C, Bennaceur-Griscelli A, Tachdjian G, Guilhot F, Guilhot J, Chomel JC, Turhan AG. Superoxide dismutase 2 (SOD2) contributes to genetic stability of native and T315I-mutated BCR-ABL expressing leukemic cells. Biochem Biophys Res Commun. 2018 Apr 15;498(4):715-722.
  23. Cayssials E, Tartarin F, Guilhot J, Sorel N, Chomel JC, Leleu X, Guilhot F. Sustained molecular response in chronic myeloid leukemia deep responders treated with low dose tyrosine kinase inhibitors. Leuk Lymphoma. 2018 Mar;59(3):766-769.
  24. Aggoune D, Sorel N, Bonnet ML, Goujon JM, Tarte K, Hérault O, Domenech J, Réa D, Legros L, Johnson-Ansa H, Rousselot P, Cayssials E, Guerci-Bresler A, Bennaceur-Griscelli A, Chomel JC, Turhan AG. Bone marrow mesenchymal stromal cell (MSC) gene profiling in chronic myeloid leukemia (CML) patients at diagnosis and in deep molecular response induced by tyrosine kinase inhibitors (TKIs). Leuk Res. 2017 Sep;60:94-102.